MedSearchGraphRAG
6 quiz questions available for this topicTake Quiz

Palliative care - oral

SNOMED: 1037350091003 words•Updated 03/03/2026
💡

Exam Tips

  • In OSCEs, always remove dentures and inspect buccal mucosa, tongue dorsum/ventrum, floor of mouth and palate before concluding.
  • Link symptom clusters to shared mechanisms: xerostomia often precedes candidiasis, pain and halitosis.
  • Differentiate candidiasis patterns: wipeable white plaques suggest pseudomembranous disease; diffuse erythema with soreness suggests erythematous disease.
  • Medication review is high-yield: anticholinergic burden commonly explains dry mouth and taste disturbance in palliative patients.
  • State safety warnings explicitly: miconazole-warfarin interaction, antimuscarinic cognitive/urinary effects, and aspiration risk with topical anaesthetics.
  • When presenting management, prioritize goals of care and reversible causes, then targeted topical/systemic therapy with clear review timing.

Definition

Oral problems in palliative care are a cluster of distressing symptoms (for example xerostomia, oral pain, halitosis, dysgeusia and sometimes hypersalivation) caused by the interaction of advanced disease, treatment effects, reduced intake and frailty. They are not a single diagnosis; they require structured oral assessment to identify reversible causes such as dehydration, candidiasis, drug effects, dental sepsis or treatment-related mucosal injury, and then targeted symptom control.

Pathophysiology

Normal oral comfort depends on intact mucosa, adequate salivary flow and local immune defence. In palliative illness, anticholinergic and other xerogenic drugs, poor fluid intake, mouth breathing, oxygen without humidification, chemotherapy/radiotherapy, local tumour effects and immune compromise disrupt this balance. Reduced saliva increases mucosal friction, lowers buffering and antimicrobial activity, and promotes plaque overgrowth and candidal colonization; this amplifies pain, ulceration, taste disturbance and malodour. Tissue hypoxia/necrosis in malignant ulcers favours anaerobes that generate volatile sulphur compounds, causing severe halitosis. Neuropathic mechanisms (post-radiotherapy nerve injury, burning mouth syndromes) can sustain pain even when mucosal signs are limited. See image references in oral medicine/oncology texts for pseudomembranous candidiasis, WHO mucositis grading and fungating oral lesions.

Risk Factors

  • Polypharmacy with xerogenic medicines (opioids, tricyclic antidepressants, SSRIs, antipsychotics, antimuscarinics, sedating antihistamines, diuretics, beta-blockers)
  • Dehydration from vomiting, diarrhoea, hypercalcaemia or uncontrolled diabetes
  • Poor oral intake or dysphagia
  • Head and neck radiotherapy or chemotherapy
  • Salivary gland damage, obstruction, infection or malignant infiltration
  • Immunosuppression/neutropenia
  • Poor oral hygiene, periodontal disease or ill-fitting dentures
  • Smoking, alcohol and strong-odour foods
  • Mouth breathing or non-humidified oxygen therapy
  • Sjögren syndrome, sarcoidosis, HIV or hepatitis C

Clinical Features

Symptoms

  • Dry mouth, sticky saliva, thirst, difficulty chewing/swallowing dry foods
  • Oral soreness or burning, pain on speaking/eating
  • Altered taste (metallic, reduced, distorted) and reduced appetite
  • Bad breath noticed by patient or carers
  • Denture discomfort or focal trauma pain
  • Hypersalivation/drooling (less common)

Signs

  • Dry, cracked mucosa; absent salivary pooling under tongue
  • Coated tongue or elongated filiform papillae
  • Erythema, ulcers, pseudomembranes or mucositis plaques
  • Removable white plaques (candidiasis) or angular cheilitis
  • Gingival bleeding, caries, periodontal inflammation, dental tenderness
  • Necrotic/malodorous tumour tissue or signs of secondary infection
  • Reduced denture fit due to alveolar resorption or mucosal injury

Investigations

Focused oral examination (good light, tongue depressor, denture-off exam):Characterizes dryness, candidiasis, ulceration, mucositis grade, dental or prosthesis-related causes
Medication review (including anticholinergic burden):Identifies potentially reversible drug-induced xerostomia or taste change
Oral swab/microbiology if diagnosis uncertain or refractory candidiasis:Candida species growth or alternative infective organism
FBC (if chemotherapy/immunosuppressed or severe ulceration):Neutropenia suggesting high-risk infective/neutropenic ulceration
U&Es, calcium, glucose when clinically indicated:Dehydration, hypercalcaemia or hyperglycaemia contributing to xerostomia
Urgent dental/maxillofacial assessment for focal tooth/jaw pain:Abscess, pulpitis, periapical disease, osteomyelitis or osteoradionecrosis

Management

Lifestyle Modifications

  • Daily mouth care protocol: soft toothbrush, gentle tongue cleaning, frequent sips of water, lip emollient
  • Avoid alcohol-containing mouthwashes, tobacco and irritant foods; optimize room humidity if feasible
  • Review and deprescribe xerogenic medicines where safe; adjust dosing times to reduce symptom burden
  • Denture hygiene and fit review; remove at night and treat pressure points
  • Treat reversible drivers (rehydration, glucose/calcium correction, infection control)

Pharmacological Treatment

Saliva replacement/stimulation for xerostomia

  • Artificial saliva spray/gel (for example carmellose-based) 1-2 sprays or applied gel as required, often every 2-4 hours
  • Pilocarpine 5 mg orally three times daily, titrated to response/tolerability (usual max 30 mg/day)

Pilocarpine is unsuitable in significant uncontrolled asthma/COPD, acute iritis and some cardiovascular disease; cholinergic adverse effects include sweating, urinary frequency and GI upset. Check interactions and overall frailty before escalation.

Oral candidiasis treatment

  • Nystatin oral suspension 100,000 units/mL: 1 mL four times daily after food (retain in mouth, then swallow), continue 48 hours after symptom resolution
  • Miconazole oral gel 24 mg/mL: 2.5 mL four times daily after food
  • Fluconazole 50 mg orally once daily for 7-14 days (consider 100 mg once daily if severe/immunocompromised)

Major safety point: avoid miconazole oral gel with warfarin due to marked INR rise/bleeding risk. Fluconazole can prolong QT and increases levels of several medicines (for example some anticoagulants, sulfonylureas, statins); check interactions and hepatic status.

Mucositis/oral pain relief

  • Benzydamine 0.15% mouthwash 15 mL every 1.5-3 hours as needed
  • Lidocaine mouthwash (5 mg/mL) 15 mL, spit or swallow as directed, no more often than every 3 hours (max 8 doses/24 h)
  • Paracetamol 1 g orally every 4-6 hours when required (max 4 g/day, lower max in low body weight/frailty as per BNF)

Topical anaesthetics can blunt gag reflex and increase aspiration risk; avoid immediately before meals in high-risk swallow patients. Escalate to systemic opioid per palliative pain guidance if pain remains severe.

Malodour from anaerobic malignant ulceration

  • Metronidazole 400 mg orally three times daily
  • Metronidazole 0.75% topical gel applied to affected lesion once or twice daily

Avoid alcohol during treatment and for 48 hours after oral metronidazole. Review for drug interactions (for example warfarin) and neuropathy risk with prolonged courses.

Troublesome hypersalivation (selected patients)

  • Glycopyrronium bromide 1 mg orally two to three times daily, titrated to effect
  • Hyoscine hydrobromide 300 micrograms buccal every 8 hours (off-label in some settings)

Antimuscarinics can worsen confusion, urinary retention, constipation and thick secretions; use cautiously in frail older adults and glaucoma/prostatic obstruction.

Surgical / Interventional

  • Urgent drainage/extraction for dental abscess where consistent with goals of care
  • Denture adjustment or remake for trauma-related pain
  • Specialist oral/maxillofacial intervention for osteoradionecrosis, osteomyelitis or refractory focal pathology
  • Debridement/local wound care planning for selected necrotic malignant lesions

Complications

  • Reduced oral intake causing dehydration, weight loss and delirium risk
  • Secondary bacterial/fungal infection of ulcerated mucosa
  • Aspiration risk from poor swallow or topical anaesthetic use
  • Bleeding/infection from severe gingival or ulcerative disease
  • Sleep disturbance, social isolation and reduced quality of life from pain/halitosis
  • Potential medicine harms from polypharmacy and drug interactions

Prognosis

Many oral symptoms improve within days to 1-2 weeks when reversible causes are treated and structured mouth care is implemented, but recurrence is common in progressive disease and ongoing xerogenic therapy. Prognosis is best with regular reassessment, medication rationalization and early dental/palliative specialist input; persistent focal pain, non-healing ulceration or trismus should trigger urgent specialist review for serious local pathology.

Sources & References

🏥BMJ Best Practice(1)

💊BNF Drug References(21)

✅NICE Guidelines(1)

📖Textbook References(20)

  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1777)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1790, 1791)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1786)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1827)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1784)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1788)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1781)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1778, 1779)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1788)[context]
  • David Randall PhD MRCP (Editor), John Booth PhD MRCP (Editor), K - Kumar and Clark's Clinical Medicine (2025, American Elsevier Publishing Co.) - libgen.li.pdf(pp. 1778)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 548, 549)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 551, 552)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 550, 551)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 547)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 875)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 7, 8)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 7, 8, 9)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 549, 550)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 539, 540)[context]
  • [Oxford Medical Handbooks] Ian Wilkinson, Tim Raine, Kate Wiles, Anna Goodhart, Catriona Ha - Oxford Handbook of Clinical Medicine (2017, Oxford University Press) - libgen.li.pdf(pp. 552)[context]

Sources

Test Your Knowledge

6 quiz questions available for this topic

Start Quiz